miR‐491‐5p functions as a tumor suppressor by targeting JMJD2B in ERα‐positive breast cancer

The involvement of miR‐491‐5p in breast cancer development is unclear. This study showed that miR‐491‐5p is significantly downregulated in ERα‐positive breast cancer tissues and cell lines and is generally hypermethylated in ERα‐positive breast cancer. MiR‐491‐5p overexpression significantly suppressed estrogen signaling and estrogen‐stimulated proliferation of breast cancer cells. Furthermore, the histone demethylase JMJD2B was identified as a direct target of miR‐491‐5p. The ectopic expression of JMJD2B abrogated the phenotypic changes induced by miR‐491‐5p in breast cancer cells. Collectively, our data indicate that miR‐491‐5p plays a tumor suppressor role in the development and progression of breast caner and may be a novel therapeutic target against ERα‐positive breast cancer.

[1]  Yuan Li,et al.  Arsenic trioxide attenuates the invasion potential of human liver cancer cells through the demethylation-activated microRNA-491. , 2014, Toxicology letters.

[2]  L. Poulain,et al.  miR-491-5p-induced apoptosis in ovarian carcinoma depends on the direct inhibition of both BCL-XL and EGFR leading to BIM activation , 2014, Cell Death and Disease.

[3]  Sung-Liang Yu,et al.  miRNA-34b as a tumor suppressor in estrogen-dependent growth of breast cancer cells , 2011, Breast Cancer Research.

[4]  B. Liu,et al.  MicroRNA miR-491-5p Targeting both TP53 and Bcl-XL Induces Cell Apoptosis in SW1990 Pancreatic Cancer Cells through Mitochondria Mediated Pathway , 2012, Molecules.

[5]  Satoru Takahashi,et al.  Distinct expressions of microRNAs that directly target estrogen receptor α in human breast cancer , 2011, Breast Cancer Research and Treatment.

[6]  F. Slack,et al.  Oncomirs — microRNAs with a role in cancer , 2006, Nature Reviews Cancer.

[7]  W. Zwart,et al.  Classification of anti-estrogens according to intramolecular FRET effects on phospho-mutants of estrogen receptor α , 2007, Molecular Cancer Therapeutics.

[8]  C. Robson,et al.  KDM4B is a Master Regulator of the Estrogen Receptor Signalling Cascade , 2013, Nucleic acids research.

[9]  B. White,et al.  The role of miR-206 in the epidermal growth factor (EGF) induced repression of estrogen receptor-alpha (ERalpha) signaling and a luminal phenotype in MCF-7 breast cancer cells. , 2009, Molecular endocrinology.

[10]  S. Ramón y. Cajal,et al.  miR-125b Acts as a Tumor Suppressor in Breast Tumorigenesis via Its Novel Direct Targets ENPEP, CK2-α, CCNJ, and MEGF9 , 2013, PloS one.

[11]  Didier Picard,et al.  miR-22 Inhibits Estrogen Signaling by Directly Targeting the Estrogen Receptor α mRNA , 2009, Molecular and Cellular Biology.

[12]  C. Robson,et al.  The lysine demethylase, KDM4B, is a key molecule in androgen receptor signalling and turnover , 2013, Nucleic acids research.

[13]  J. Ragoussis,et al.  The histone demethylase JMJD2B is regulated by estrogen receptor alpha and hypoxia, and is a key mediator of estrogen induced growth. , 2010, Cancer research.

[14]  Yang Shi,et al.  Reversal of Histone Lysine Trimethylation by the JMJD2 Family of Histone Demethylases , 2006, Cell.

[15]  R. Janknecht,et al.  KDM4/JMJD2 histone demethylases: epigenetic regulators in cancer cells. , 2013, Cancer research.

[16]  W. Filipowicz,et al.  The widespread regulation of microRNA biogenesis, function and decay , 2010, Nature Reviews Genetics.

[17]  Early Breast Cancer Trialists' Collaborative Group.  Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials , 2011, The Lancet.

[18]  Jing Liang,et al.  Histone demethylase JMJD2B coordinates H3K4/H3K9 methylation and promotes hormonally responsive breast carcinogenesis , 2011, Proceedings of the National Academy of Sciences.

[19]  T. Mak,et al.  Histone Demethylase JMJD2B Functions as a Co-Factor of Estrogen Receptor in Breast Cancer Proliferation and Mammary Gland Development , 2011, PloS one.

[20]  Anwar Hossain,et al.  Mir-17-5p Regulates Breast Cancer Cell Proliferation by Inhibiting Translation of AIB1 mRNA , 2006, Molecular and Cellular Biology.

[21]  Z. Lu,et al.  MiR-873 regulates ERα transcriptional activity and tamoxifen resistance via targeting CDK3 in breast cancer cells , 2014, Oncogene.

[22]  W. Gallagher,et al.  microRNAs: a new class of breast cancer biomarkers , 2014, Expert review of molecular diagnostics.

[23]  C. Sotiriou,et al.  Global MicroRNA Expression Profiling Identifies MiR-210 Associated with Tumor Proliferation, Invasion and Poor Clinical Outcome in Breast Cancer , 2011, PloS one.

[24]  T. Yen,et al.  miRNA-491-5p and GIT1 serve as modulators and biomarkers for oral squamous cell carcinoma invasion and metastasis. , 2014, Cancer research.

[25]  J. Bao,et al.  A Systematic In Silico Mining of the Mechanistic Implications and Therapeutic Potentials of Estrogen Receptor (ER)-α in Breast Cancer , 2014, PloS one.

[26]  Olli Kallioniemi,et al.  High‐throughput screens identify microRNAs essential for HER2 positive breast cancer cell growth , 2014, Molecular oncology.

[27]  N. Miller,et al.  Interactions between the estrogen receptor, its cofactors and microRNAs in breast cancer , 2009, Breast Cancer Research and Treatment.

[28]  K. Helin,et al.  Histone methyltransferases in cancer. , 2010, Seminars in cell & developmental biology.

[29]  J. Whetstine,et al.  Histone lysine methylation dynamics: establishment, regulation, and biological impact. , 2012, Molecular cell.

[30]  C. Croce,et al.  Breast cancer signatures for invasiveness and prognosis defined by deep sequencing of microRNA , 2012, Proceedings of the National Academy of Sciences.

[31]  J. Carroll,et al.  Estrogen and antiestrogen regulation of cell cycle progression in breast cancer cells. , 2003, Endocrine-related cancer.

[32]  C. Croce,et al.  Epigenetically deregulated microRNA-375 is involved in a positive feedback loop with estrogen receptor alpha in breast cancer cells. , 2010, Cancer research.

[33]  Andrea Sottoriva,et al.  The shaping and functional consequences of the microRNA landscape in breast cancer , 2013, Nature.

[34]  Hui Li,et al.  MiR-31 is an independent prognostic factor and functions as an oncomir in cervical cancer via targeting ARID1A. , 2014, Gynecologic oncology.

[35]  Simak Ali,et al.  Antiestrogens and their therapeutic applications in breast cancer and other diseases. , 2011, Annual review of medicine.

[36]  Hui Li,et al.  Increased expression of RRM2 by human papillomavirus E7 oncoprotein promotes angiogenesis in cervical cancer , 2014, British Journal of Cancer.

[37]  M. Dowsett,et al.  Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer. , 1995, Cancer research.

[38]  Jianping Zhang,et al.  MicroRNA‐491 is involved in metastasis of hepatocellular carcinoma by inhibitions of matrix metalloproteinase and epithelial to mesenchymal transition , 2013, Liver international : official journal of the International Association for the Study of the Liver.

[39]  N. Kondo,et al.  miR-206 Expression is down-regulated in estrogen receptor alpha-positive human breast cancer. , 2009, Cancer research.